2018 Transplant Hepatology Board Review Course

4.88 (26 votes)

Recorded On: 08/19/2018

This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

Online Course Pricing:

  • Member — $325
  • Trainee and Associate Member — $185
  • Nonmember — $540
  • Nonmember Trainee / Associate — $235
  • Industry — $775

Core Competencies

  • Patient care and Procedural Skills
  • Medical knowledge
  • Practice-based learning and improvement
  • Patient-centered care
  • Evidence-based practice
  • Quality improvement
  • Values/Ethics for inter-professional practice

Program Chairs:

  • K. Gautham Reddy, MD, FAASLD
  • Oren K. Fix, MD, MSc, FAASLD
  • Laura M. Kulik, MD

Components

29 online interactive recorded sessions, 20-30 minutes in length
Post-activity quiz for each session

Release Date: September 14, 2018
Expiration Date: September 13, 2020

Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

K. Gautham Reddy (Moderator)

Gautham Reddy, MD is a transplant hepatologist and gastroenterologist who currently serves as the Associate Chief in the Section of Gastroenterology, Hepatology & Nutrition at The University of Chicago Medicine. He has an avid interest in medical education and previously served for many years as the Program Director for both the Gastroenterology Fellowship and the Transplant Hepatology Fellowship at The University of Chicago. He has been a recipient of teaching and mentorship awards and has served on multiple AASLD and ACG committees related to training and education. His research interests include novel therapeutics for rare hepatology conditions and medical education.

Oren K. Fix (Moderator)

Dr. Oren Fix is the Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle, Washington, Clinical Associate Professor at the Washington State University Elson S. Floyd College of Medicine, and Associate Provider Informaticist at Providence St. Joseph Health. He is board certified in Transplant Hepatology, Gastroenterology, Internal Medicine, and Clinical Informatics. He is the co-chair for the AASLD COVID-19 Task Force's Clinical Oversight Subcommittee, and serves on the AASLD Nominating Committee, Online Learning Committee, and the GI/Transplant Hepatology Pilot Steering Task Force. He is on the editorial boards of Liver Transplantation and Hepatology Communications. Past service to AASLD includes chair of the Training and Workforce Committee and chair of the MOC Committee.

Laura M. Kulik (Moderator)

I am a Professor of Medicine in the Division of Gastroenterology and Hepatology, and am Certified in both Gastroenterology and Hepatology and in Transplant Hepatology. My major clinical research focus is on the therapy and diagnosis of hepatocellular carcinoma. I work in a muliti-disciplinary medical/radiologic/surgical Liver Tumor clinic, and am involved in the recruitment of patients with HCC into clinical or pathologic trials. My major interest is on loco-regional therapy for HCC, both as a primary therapy and as a bridge to liver transplantation, including 90Yttrium radiotherapy and TACE.

Michael R. Lucey

Dr Michael Ronan Lucey was born in Dublin, Ireland, and was educated at Trinity College, Dublin, graduating with the degrees of M.B., B.Ch in 1976.  He was awarded an M.D. by thesis in 1985. He completed his internship at the Meath Hospital, Dublin and residency in Internal Medicine at the Federated Dublin Voluntary Hospitals.  He was a fellow in Gastroenterology at Saint Bartholomew's Hospital, and a fellow in Liver Diseases in Kings College Hospital, both in London, England.  In 1985 he came to the University of Michigan, first as a fellow and then as faculty in the Division of Gastroenterology.  While at the University of Michigan, he became Medical Director of the liver transplant program.  From 1995 to 2001, he was Director of Hepatology at the University of Pennsylvania.  In 2001until the present,  he has been Professor of Medicine, Chief of the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. 

Dr Lucey's research interests include selection for and outcome of liver transplantation, alcoholic liver disease, and management of end-stage liver disease.  Dr Lucey was president of the American Society of Transplantation in 2003. He was treasurer of the American Association for the Study of Liver Diseases from 2007 to 2010. 

He was Editor in Chief of Clinical Liver Disease, the on-line educational journal of the AASLD from 2011 to 2017.  

Julie Heimbach

Michael R. Charlton

Marina G. Silveira

Jennifer C. Lai

Dr. Lai is a transplant hepatologist, Associate Professor In Residence at the University of California, San Francisco and Director of the UCSF Hepatology Clinical Research.

Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation. Her primary research focuses on integrating core geriatric principles, such as frailty and palliative care, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients. She is the founder and principal investigator of the NIH funded Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes. She serves as an Associate Editor for the American Journal of Transplantation and Editorial Board Member of Hepatology and Liver Transplantation journals, as well as a standing member of the FDA GI Drug Advisory Committee. In 2020, she was appointed chair the AASLD Practice Guidance on Frailty, Sarcopenia, and Malnutrition. In recognition of the importance of her work, Dr. Lai has been named a NIH Beeson Scholar in Aging Research by the National Institute on Aging and was awarded the American Gastroenterological Association Young Investigator Award in 2020.

Philip Rosenthal

Michael F. Chang

Josh Levitsky

Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine where he was elected to Alpha Omega Alpha. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. At Northwestern, he completed a Master of Science in Clinical Investigation. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology.

Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is a Deputy Editor for the American Journal of Transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. At Northwestern, he is currently the Gastroenterology Program Director and Director of Liver Research. He has been elected to the Feinberg Academy of Medical Educators and has received several teaching awards.

Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation, American Association for the Study of Liver Diseases, and the International Liver Transplantation Society. He was previously a Councilor-At-Large for the American Society of Transplantation from 2014-2017. He was a prior chair of the American Transplant Congress, recent co-chair of AST’s CEOT meeting and is the current co-chair of the AST Education Committee. One of his passions is trainee education, establishing the AST Comprehensive Trainee Curriculum and regularly participating in the yearly Fellow’s Symposium. Dr. Levitsky’s dedication to the field of transplantation and AST includes all facets of clinical care, advocacy, research and education.

Robert J. Fontana

Jacquelyn F. Fleckenstein

Dr. Fleckenstein is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Washington University School of Medicine in St. Louis, Missouri.  She is interested in the management of advanced cirrhosis and pregnancy related liver disease.  She serves as the director of the liver transplant fellowship program at Washington University and she has served on several AASLD committees. 

Steven L. Flamm

Scott W. Biggins

Dr. Scott W. Biggins is Chief of Hepatology, Director of the Liver Care Line for UW Medicine, and Director of the Center for Liver Investigation Fostering Discovery (C-LIFE) at the University of Washington. Dr. Biggins is a national recognized clinician and researcher in the field of Hepatology. He received his undergraduate degree in chemical engineering (bioengineering option) from the University of California, Los Angeles (1994) and his medical degree from the University of Southern California (1999). He completed a residency in Internal Medicine at Oregon Health & Science University (2002) and his Gastroenterology fellowship training at the University of California, San Francisco (2005). He was also awarded a Master’s degree in Clinical Research from the University of California, San Francisco (2006).

Dr. Biggins' clinical interests are the risk reduction and management of complications of end-stage liver disease, and the clinical evaluation and care of liver transplant candidates and recipients. He has been recognized as a fellow of American Association for the Study of Liver Diseases (FAASLD), American Society of Transplantation (FAST), and American Gastroenterological Association (AGAF). He is Vice Chair of the AASLD Special Interest Group (SIG) for Portal Hypertension.

His research is focused on complications of portal hypertension, improving recipient and donor selection for liver transplantation and revising organ allocation algorithms in order to maximize patient outcomes. He has received research funding from the American Liver Foundation, National Institutes of Health and the Agency for Healthcare Research and Quality. He has published more than 75 papers in peer-reviewed journals including the New England Journal of MedicineGastroenterology, HEPATOLOGY, and Liver Transplantation.

Carl L. Berg

Dr. Berg is Professor of Medicine and Medical Director of Abdominal Transplantation at Duke University.  He has been a director of liver transplant programs for more than 20 years, and trained nearly twenty transplant hepatologists over that time frame.  He has served in numerous national roles related to management of the US transplant system, including as President of UNOS.  His research interests focus on expanding the donor pool to better match organ demand, as well as utilization of organs previously considered as “marginal”.

 

Sandy Feng

Norah A. Terrault

Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

 

 

Peter Chin-Hong

Peter Chin-Hong is Associate Dean for Regional Campuses. He is a medical educator who specializes in treating infectious diseases, particularly infections that develop in patients who have suppressed immune systems, such as solid organ and hematopoietic stem cell transplant recipients and HIV+ organ transplant recipients. He directs the immunocompromised host infectious diseases program at UCSF. His research focuses on donor derived infections in transplant recipients and molecular diagnostics of infectious diseases in patients with suppressed immune systems. He earned his undergraduate and medical degrees from Brown University, before completing an internal medicine residency and infectious diseases fellowship at UCSF, where he is Professor of Medicine and Director of the Yearlong Inquiry Program in the School of Medicine. He was the inaugural holder of the Academy of Medical Educators Endowed Chair for Innovation in Teaching. He was a member of UNOS/OPTN Disease Transmission Advisory Committee and is Associate Medical Director of Donor Network West.

Michael D. Leise

Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

Mark W. Russo

Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. In the AASLD, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine.  He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.

Philip Rosenthal

Andrew I. Aronsohn

Andrew Aronsohn is an Associate Professor of Medicine in the Center for Liver Diseases at the University of Chicago Medical Center. Dr. Aronsohn is the program director for the Gastroenterology fellowship at the University of Chicago. In addition, Dr. Aronsohn is a faculty member at the MacLean Center for Clinical Medical Ethics at the University of Chicago and is the co-director of the Pritzker School of Medicine Doctor Patient Relationship course.  Dr. Aronsohn research interests involve HCV education, access to care and elimination. He is the co-principal investigator of HepCCATT, an initiative to diagnose, link to care and treat HCV in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting.  Dr. Aronsohn is the co-lead of the treatment experienced section of the AASLD / IDSA HCV guidance writing committee as was a member of National Academies of Medicine committee which wrote “A National Strategy for the Elimination of Hepatitis B and C”. He also has a busy clinical practice, which includes both general and transplant hepatology.

Lisa VanWagner

Dr. Lisa VanWagner is an Assistant Professor of Medicine-GI & Hepatology and Preventive Medicine-Epidemiology at Northwestern University in Chicago, IL.  Dr. VanWagner utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease (risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Notably, she leads the multicenter Advancing Liver Therapeutic Approaches (ALTA) Consortium Study Group for the Management of Portal Hypertension and is the lead Principal investigator for ALTA TIPS, a U.S. based longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their standard of care in hopes of answering key clinical questions about the utilization, outcomes and best practices surrounding TIPS as a therapeutic intervention for the complications of portal hypertension.  She is an active member of AASLD, currently serving as a member of the Practice Guidelines Committee and is an Associate Editor for Liver Transplantation and Clinical Liver Disease.

Key:

Complete
Failed
Available
Locked
Session I
Introduction
Open to view video.
Open to view video.
Liver Transplantation for Cholangiocarcinoma and Other Rare Tumors
Open to view video.
Open to view video.
Perioperative Complications
Open to view video.
Open to view video.
Liver Transplantation for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
Open to view video.
Open to view video.
Cholestatic and Autoimmune Liver Diseases
Open to view video.
Open to view video.
Nutritional Support in the Perioperative Setting Nutritional Support in Patients with Cirrhosis
Open to view video.
Open to view video.
Breakout (Adult): Alcoholic Liver Disease
Open to view video.
Open to view video.
Metabolic and Genetic Diseases I
Open to view video.
Open to view video.
Metabolic and Genetic Diseases II
Open to view video.
Open to view video.
Transplant Immunology
Open to view video.
Open to view video.
Immunosuppression and Rejection
Open to view video.
Open to view video.
Session I Quiz
10 Questions  |  Unlimited attempts  |  7/10 points to pass
10 Questions  |  Unlimited attempts  |  7/10 points to pass
Session II
Drug-Induced Liver Disease and Acute Liver Failure
Open to view video.
Open to view video.
Liver Diseases of Pregnancy
Open to view video.
Open to view video.
Hepatitis C Virus Infection: Pre- and Post-Liver Transplantation
Open to view video.
Open to view video.
Portal Hypertension
Open to view video.
Open to view video.
Selection and Evaluation for Transplantation
Open to view video.
Open to view video.
Donor Selection
Open to view video.
Open to view video.
Management of Hepatitis B and D in the Transplant Setting
Open to view video.
Open to view video.
Surgical Options and Complications Specific to Graft and Donor Types and Living Donors
Open to view video.
Open to view video.
Session II Quiz
8 Questions  |  Unlimited attempts  |  6/8 points to pass
8 Questions  |  Unlimited attempts  |  6/8 points to pass
Session III
Introduction
Open to view video.
Open to view video.
HCC and Post-Transplant Malignancy
Open to view video.
Open to view video.
Post Liver Transplant Infectious Complications
Open to view video.
Open to view video.
Recurrence of Disease After Liver Transplantation
Open to view video.
Open to view video.
Long Term Complications Post Liver Transplant
Open to view video.
Open to view video.
Breakout: Pediatric Topics
Open to view video.
Open to view video.
Potpourri
Open to view video.
Open to view video.
Ethics and Liver Transplantation
Open to view video.
Open to view video.
Statistics for the Boards
Open to view video.
Open to view video.
Wrap Up
Open to view video.
Open to view video.
Session III Quiz
12 Questions  |  Unlimited attempts  |  9/12 points to pass
12 Questions  |  Unlimited attempts  |  9/12 points to pass
Credits, Certificates, & Evaluation
CME Credits
Up to 11.50 medical credits available  |  Certificate available
Up to 11.50 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
MOC Points
Up to 11.50 medical credits available  |  Certificate available
Up to 11.50 medical credits available  |  Certificate available
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.

Upon completion of this activity, learners will be able to: 

  • Discuss the diagnosis, natural history, and therapies for liver diseases leading to liver transplantation;
  • Discuss the management of patients awaiting liver transplantation;
  • Discuss the immediate post-operative and long-term management of liver transplant recipients;
  • Discuss current organ allocation policy and its effects on selecting potential liver transplant recipients.


  • Hepatologists
  • Fellows/ Trainees

Satisfactory completion 

Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

CME 

Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation AASLD designates this enduring activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Maintenance of Certification

American Board of Internal Medicine (ABIM) MOC Statement 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics (ABP) MOC Statement

“Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 11.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

MOC Points Process

Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.


DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The organizers and faculty have reported the following disclosures:

Andrew I. Aronsohn, MD
Faculty
Nothing to Disclose

Carl L. Berg, MD, FAASLD
Faculty Scientific
Consulting: Dova Pharnaceuticals, Grifols

Scott W. Biggins, MD, MAS, FAASLD
Faculty
Nothing to Disclose

Michael F. Chang, MD, MSc
Faculty
Nothing to Disclose

Michael R. Charlton, MD, FRCP
Faculty
Grant/Research Support: Intercept, GIlead Sciences, Merck, Janssen, AbbVie, Novartis Scientific
Consulting: Gilead Sciences

Peter Chin-Hong, MD
Faculty
Grants/Research Support: Karius

Sandy Feng, MD, PhD
Faculty
Stock/Stock Options: Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira, Amgen, Johnson & Johnson, Stryker
Advisory Committees and/or Review Panels: Juno Therapeutics, Inc., American Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine
Grants/Research Support: Novartis, Quark

Oren K. Fix, MD, MSc, FAASLD
Faculty
Nothing to Disclose

Steven L. Flamm, MD
Faculty
Nothing to Disclose

Jacquelyn F. Fleckenstein, MD, FAASLD
Faculty
Nothing to Disclose

Robert J. Fontana, MD, FAASLD
Faculty
Scientific Consulting: Alynam Pharmaceuticals
Grants/Research Support: BMS, Gilead, Abbvie

Julie Heimbach, MD, FAASLD
Faculty
Nothing to Disclose

Laura M. Kulik, MD
Faculty
Nothing to Disclose

Jennifer C. Lai, MD
Faculty
Scientific Consulting: Third Rock Ventures, LLC

Michael D. Leise, MD
Faculty
Nothing to Disclose

Josh Levitsky, MD, FAASLD
Faculty
Grants/Research Support: Novartis Scientific
Consulting: Novartis
Speakers Bureau: Gilead, Salix

Michael R. Lucey, MD, FAASLD 
Faculty
Grant/Research Support: Abbvie, Gilead, Pharmasoluions

Jorge A. Marrero, MD
Faculty
Scientific Consulting: Eisai, Grail, Exelis, Astra Zeneca

K. Gautham Reddy, MD, FAASLD
Faculty
Grants/Research Support: Merck, Intercept, Genfit
Scientific Consulting: Intercept
Speaker's Bureau: Intercept Dova Advisory
Committees and/or Review Panels: American College of Gastroenterology

Philip Rosenthal, MD, FAASLD
Faculty
Grants/Research Support: Gilead Scientific
Consulting: Gilead, Retrophin, Albireo

Mark W. Russo, MD, MPH, FAASLD
Faculty
Speakers Bureau: Gilead, Abbvie, Intercept, Salix

Marina G. Silveira, MD  
Faculty
Scientific Consulting: Conatus

Norah Terrault, MD, MPH, FAASLD
Faculty
Scientific Consulting: CME, CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
Advisory Committees or Review Panels: Merck, Intercept, Conatus, Dova
Grant/Research Support: AbbVie, Eisai, Gilead, BMS, Merck, Allergan, Biotest
Royalties: UpToDate

Lisa B. VanWagner, MD, MSc
Faculty
Grants/Research Support: Advanced MR Analytics (AMRA) Medical

Maintenance of Certification Committee

Oren K. Fix, MD, MSc, FAASLD
Chair
Nothing to disclose

Mark W. Russo, MD, MPH, FAASLD
Vice-Chair
Commercial Speaker's Bureau: Gilead, Abbvie,Intercept, Salix

Raymond T. Chung, MD, FAASLD
Board Liaison
Research Grants: Abbvie, Gilead Sciences, Boehringer Ingelheim

Curtis K. Argo, MD, MS, FAASLD
Member
Nothing to disclose

Steven K. Herrine, MD, FAASLD
Member
Research Grants: Gilead, BMS, Galectin, Interecept 
Leadership in related society: Board, Committee, Journal: ABIM - Chair, Transplant Hepatology Test Committee

Vandana Khungar, MD, MSc
Member
Nothing to disclose

Ayman A. Koteish, MD, FAASLD
Member
Nothing to disclose

Smruti R. Mohanty, MD, MS
Member
Advisory Board: Gilead science, Abbvie, Merck, Bristol Meyers Squib and Intercept
Leadership in related society: Board, Committee, Journal: Publications Committee, American College of Gastroenterology (2009- Present) Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology

Heather M. Patton, MD, FAASLD
Member
Nothing to disclose

K. Gautham Reddy, MD, FAASLD
Member
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept, Gilead
Research Grants: Merck Intercept Genfit
Commercial Speaker's Bureau: Intercept
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of;

Grace L. Su, MD, FAASLD
Member
Company: Management Position

Ryan M. Taylor, MD
Member
Commercial Speaker's Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

Helen S. Te, MD, FAASLD
Member
Research Grants: Conatus Pharmaceuticals, Abbvie, Gilead Sciences
Advisory Board: Gilead Sciences,Intercept Pharmaceuticals

Debra Guss, RN, NP-C, ACRN
Associate
Nothing to disclose

Katie Duggan, BA
Staff Liaison
Nothing to disclose

Training and Workforce Committee

K. Gautham Reddy, MD, FAASLD
Chair
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology;
Research Grants: Merck Intercept Genfit; Commercial Speaker's Bureau: Intercept Dova; Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept

Raymond T. Chung, MD, FAASLD
Board Liaison
Research Grants: BMS, Roche,Gilead Sciences, Abbvie, Boehringer Ingelheim

Christopher L. Bowlus, MD, FAASLD
Member
Research Grants: Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, NGM Biosciences, GlaxoSmithKline, Merck, BristolMyerSquibb, TARGET Pharmasolutions, Genkyotex, Allergan, JKB Taiwan Pharmaceuticals
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Intercept Pharmaceuticals, GlaxoSmithKline, BristolMyersSquibb, Conatus, Patara, Eli Lilly

Michael F. Chang, MD, MSc, FAASLD
Member
Nothing to disclose

Hari S. Conjeevaram, MD, MS
Member
Nothing to disclose

Amy Feldman, MD
Member
Nothing to disclose

Aparna Goel, MD
Member
Nothing to disclose

Seth J. Karp, MD
Member
Nothing to disclose

Michael D. Leise, MD
Member
Nothing to disclose

Sylvia M. Lempit, MSN
Associate Member
Nothing to disclose

Michelle Long, MD
Member
Research Grants: Echosens

Ian R. Schreibman, MD
Member
Nothing to disclose

Jessica Davis, MD
Trainee
Nothing to disclose

Omar Y. Mousa, MD
Trainee
Nothing to disclose

Katie Duggan, BA
Staff Liaison
Nothing to disclose

Janeil Klett
Staff Liaison
Nothing to disclose